Literature DB >> 7137981

Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure.

D C Blair, D O Duggan, E T Schroeder.   

Abstract

Aminoglycosides are inactivated by carbenicillin in vitro and in patients with end-stage renal failure. In vitro, amikacin is inactivated to a lesser extent than is gentamicin. In five patients on chronic hemodialysis, serum levels of amikacin alone and after repeated intravenous carbenicillin infusions were determined. Analogous gentamicin studies were conducted with five different patients. Neither amikacin serum levels nor serum clearances were affected by carbenicillin. The mean gentamicin serum half-life was significantly lower in the presence of carbenicillin: 18.4 +/- 8.2 compared with 61.6 +/- 30.7 h. Serum clearance increased significantly. The inactivation of gentamicin by carbenicillin was both time related (greater than 12 h of exposure) and concentration dependent (molar carbenicillin/gentamicin ratios greater than or equal to 39:1). Amikacin would be preferable to gentamicin in patients with end-stage renal failure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7137981      PMCID: PMC183751          DOI: 10.1128/AAC.22.3.376

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Interactions of carbenicillin and ticarcillin with gentamicin.

Authors:  M Davies; J R Morgan; C Anand
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  Inactivation of gentamicin by penicillins in patients with renal failure.

Authors:  F R Ervin; W E Bullock; C E Nuttall
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Gentamicin pharmacokinetics during hemodialysis.

Authors:  T G Christopher; D Korn; A D Blair; A W Forrey; M A O'Neill; R E Cutler
Journal:  Kidney Int       Date:  1974-07       Impact factor: 10.612

4.  Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

Authors:  J E McLaughlin; D S Reeves
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

5.  Therapeutic implications of interaction of gentamicin and penicillins.

Authors:  P Noone; J R Pattison
Journal:  Lancet       Date:  1971-09-11       Impact factor: 79.321

6.  Antibiotic synergy in experimental infection with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin.

Authors:  V T Andriole
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

7.  Laboratory and clinical conditions for gentamicin inactivation by carbenicillin.

Authors:  L J Riff; G G Jackson
Journal:  Arch Intern Med       Date:  1972-12

8.  Combined use of gentamicin and carbenicillin.

Authors:  R E Winters; A W Chow; R H Hecht; W L Hewitt
Journal:  Ann Intern Med       Date:  1971-12       Impact factor: 25.391

9.  Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study.

Authors:  P Stevens; L S Young; W L Hewitt
Journal:  J Lab Clin Med       Date:  1975-08

10.  In-vitro activity of carbenicillin and results of treatment of infections due to Pseudomonas with carbenicillin singly and in combination with gentamicin.

Authors:  C B Smith; J N Wilfert; P E Dans; T A Kurrus; M Finland
Journal:  J Infect Dis       Date:  1970-09       Impact factor: 5.226

View more
  13 in total

1.  Interactions of ceftazidime and tobramycin in patients with normal and impaired renal function.

Authors:  G R Aronoff; R A Brier; R S Sloan; M E Brier
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

3.  Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.

Authors:  C E Halstenson; C A Hirata; K L Heim-Duthoy; P A Abraham; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Role of sodium in protection by extended-spectrum penicillins against tobramycin-induced nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Effect of piperacillin on tobramycin pharmacokinetics in patients with normal renal function.

Authors:  A Lau; M Lee; S Flascha; R Prasad; R Sharifi
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  Attenuation of experimental tobramycin nephrotoxicity by ticarcillin.

Authors:  J English; D N Gilbert; S Kohlhepp; P W Kohnen; G Mayor; D C Houghton; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

7.  In vitro inactivation of aminoglycosides by sulbactam, other beta-lactams, and sulbactam-beta-lactam combinations.

Authors:  P C Fuchs; S Stickel; P H Anderson; A L Barry; S Shilling
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

8.  Comparative assessment of in vitro inactivation of gentamicin in the presence of carbenicillin by three different gentamicin assay methods.

Authors:  S C Ebert; J H Jorgensen; D J Drutz; W A Clementi
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

9.  In vitro interaction of aminoglycosides with beta-lactam penicillins.

Authors:  S M Wallace; L Y Chan
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

10.  Radioenzymatic assays for aminoglycosides with kanamycin 6'-acetyltransferase.

Authors:  A Weber; A L Smith; K E Opheim
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.